|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
| Formula | C15H14N2O4S |
||||||||||||||
| Molecular Weight | 318.35 | CAS No. | 866323-14-0 | ||||||||||||
| Solubility (25°C)* | In vitro | DMSO | 64 mg/mL (201.03 mM) | ||||||||||||
| Ethanol | 64 mg/mL (201.03 mM) | ||||||||||||||
| Water | Insoluble | ||||||||||||||
| In vivo (Add solvents to the product individually and in order) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||||||||||
| Description | Belinostat is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. This compound could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. [1] It inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. [2] The growth inhibitory activity of this chemical on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. It could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. This compound also shows enhanced tubulin acetylation in ovarian cancer cell lines. [3] A recent study shows that it activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA. [4] | ||
| In vivo | Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. [1] This compound also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. [2] Its monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of this chemical (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. [3] Combining with bortezomib, it results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft. [5] | ||
| Features | Lead compound of Topotarget. |
| Kinase Assay:[1] |
|
|---|---|
| Cell Assay:[1] |
|
| Animal Study:[1] |
|
|

Data from [ Breast Cancer Res Treat , 2012 , 131, 777-789 ]

Data from [ PLoS One , 2011 , 6, e17138 ]

Data from [ PLoS One , 2011 , 6, e17138 ]

Data from [ Breast Cancer Res Treat , 2010 , 131(3), 777-789 ]
| A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8] | PubMed: 40147445 |
| Deacetylation of TALDO1 by HDAC6 promotes glycolysis and nasopharyngeal carcinoma progression through a moonlighting function [ Cell Death Dis, 2025, 16(1):743] | PubMed: 41120289 |
| The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer [ Mol Oncol, 2025, 10.1002/1878-0261.70050] | PubMed: 40483575 |
| The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xL or Mcl-1 in ovarian cancer [ Mol Oncol, 2025, 10.1002/1878-0261.70050] | PubMed: 40483575 |
| Targeting the akt/mtor signaling pathway by maprotiline leads to tumor suppression in T-cell lymphoma [ Ann Hematol, 2025, 10.1007/s00277-025-06571-z] | PubMed: 40892074 |
| Role of the NuRD complex and altered proteostasis in cancer cell quiescence [ bioRxiv, 2025, 2025.02.10.637435] | PubMed: 39990343 |
| Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML [ Nat Commun, 2024, 15(1):4739] | PubMed: 38834613 |
| Interferon-induced factor 16 is essential in metastatic melanoma to maintain STING levels and the immune responses upon IFN-γ response pathway activation [ J Immunother Cancer, 2024, 12(10)e009590] | PubMed: 39424359 |
| Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression [ Cell Rep, 2024, 43(1):113575] | PubMed: 38181788 |
| PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A [ J Transl Med, 2024, 22(1):1047] | PubMed: 39568000 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.